Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCPA.L Regulatory News (SCPA)

  • There is currently no data for SCPA

Trading Update

12 Feb 2020 07:00

RNS Number : 6939C
Scapa Group PLC
12 February 2020
 

12 February 2020

 

LEI No. 213800QIPVTK5ES5UU36

 

 

Scapa Group plc

 

Trading Update

 

Scapa Group plc (AIM: SCPA) provides an update on current trading ahead of its financial year-end on 31 March 2020.

 

The Group expects FY20 revenue to be approximately ÂŁ306 million, broadly in line with market expectations. However, trading profit is now expected to be approximately ÂŁ28 million, significantly below consensus.

 

Healthcare revenue is estimated to be approximately ÂŁ139 million, slightly ahead of market expectations and greater than last year despite the loss of the ConvaTec contract. Healthcare trading profit is expected to be lower than consensus, reflecting slower progress in reducing costs than expected at the time of the interim results. The Group continues to focus on our pipeline of new programs as we leverage our technologies and capabilities to drive our organic growth and reduce the cost of operations.

 

Industrial revenue is expected to be approximately ÂŁ168 million, which is slightly below market expectations but has a material impact on Group trading profit. This is primarily the result of adverse macroeconomic conditions, particularly in the automotive and specialty products markets.

 

The Group is focused on rigorous execution of the strategy as it continues to increase efficiency and convert its pipeline of opportunities to improve sales and margin performance. The Group expects the macro environment to remain challenging in some of the industrial markets in which it operates.

 

We believe that we have the right vision and strategy to capitalize on the outlook and opportunities for Healthcare and Industrial. Our Healthcare franchise is well positioned to benefit from the changes in the medical device market and whilst we expect the macro-environment to remain challenging, we will focus on cost reductions to drive the margin in Industrial to historical levels.

 

Scapa expects to report its full year results on 19 May 2020.

 

 

For further information:

 

Scapa Group plc

Heejae Chae - Group Chief Executive

Oskar Zahn - Chief Financial Officer

 

Tel: 0161 301 7430

Numis Securities Limited

(Nominated Adviser/Joint Broker)

 

Mark Lander, Freddie Barnfield

Tel: 020 7260 1000

Berenberg

(Joint Broker)

 

Chris Bowman, Toby Flaux

 

Tel: 020 3207 7800

FTI Consulting

(Media Relations)

 

Simon Conway, Victoria Foster Mitchell

Tel: 020 3727 1000

 

 

 

 

About Scapa Group plc

Scapa Group plc is a diversified Healthcare and Industrial company focused on bringing best-in-class innovation, design and manufacturing solutions to its customers.

 

Healthcare

Scapa Healthcare is the trusted strategic partner of choice for the world's leading companies in Advanced Wound Care, Consumer Wellness and Medical Device Fixation. We partner with the top global MedTech companies to develop and manufacture innovative skin friendly medical device fixation and topical solutions, from inception through to market delivery, from our state-of-the-art facilities.

 

For further information, please visit www.scapahealthcare.com

 

Industrial

Scapa Industrial is a global supplier of bonding solutions and manufacturer of adhesive-based products which offer meaningful value in industrial applications due to their lightweight, easy-to-apply properties. We are recognised for our unparalleled range of products, including adhesive tapes, films and foams, and we can engineer custom designs for even the most unique applications.

 

For further information, please visit www.scapaindustrial.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTEADAFFDDEEAA
Date   Source Headline
1st Mar 201710:22 amRNSAdditional Listing
23rd Feb 201711:03 amRNSHolding(s) in Company
16th Feb 20179:21 amRNSHolding(s) in Company
7th Feb 20174:16 pmRNSBlock listing Interim Review
3rd Feb 20173:53 pmRNSHolding(s) in Company
26th Jan 201710:10 amRNSDirector/PDMR Shareholding
25th Jan 20174:33 pmRNSBlock listing Interim Review
25th Jan 201711:49 amRNSHolding(s) in Company
23rd Jan 20179:18 amRNSDirector/PDMR Shareholding
9th Jan 20179:41 amRNSAdditional Listing
22nd Dec 20162:15 pmRNSAdditional Listing
15th Dec 20167:00 amRNSDirectorate Change
13th Dec 20161:29 pmRNSAdditional Listing
24th Nov 20164:30 pmRNSDirector/PDMR Shareholding
24th Nov 20164:20 pmRNSDirector/PDMR Shareholding
22nd Nov 20164:20 pmRNSAdditional Listing
22nd Nov 20167:00 amRNSHalf-year Report
12th Oct 20167:00 amRNSTrading Statement
27th Sep 20162:53 pmRNSDirector/PDMR Shareholding
21st Sep 20161:51 pmRNSAdditional Listing
6th Sep 201610:24 amRNSAdditional Listing
2nd Sep 201611:20 amRNSBlock listing Interim Review
31st Aug 20169:14 amRNSTotal Voting Rights
26th Aug 20167:00 amRNSDirector/PDMR Shareholding
12th Aug 201611:24 amRNSBlock listing Interim Review
11th Aug 20161:30 pmRNSDirector/PDMR Shareholding
10th Aug 201610:08 amRNSDirector/PDMR Shareholding
19th Jul 20164:58 pmRNSAdditional Listing
19th Jul 20167:00 amRNSAGM Statement
11th Jul 20163:48 pmRNSDirector/PDMR Shareholding
5th Jul 20162:25 pmRNSHolding(s) in Company
1st Jul 20162:58 pmRNSDirector/PDMR Shareholding
1st Jun 20163:49 pmRNSAdditional Listing
1st Jun 20167:00 amRNSAppointment of Joint Broker
24th May 20167:00 amRNSAcquisition
24th May 20167:00 amRNSFinal Results
18th May 201610:01 amRNSAdditional Listing
11th May 201610:45 amRNSHolding(s) in Company
18th Apr 20167:00 amRNSDirectorate Change
14th Apr 20167:00 amRNSTrading Statement
2nd Mar 20169:06 amRNSBlocklisting Interim Review
8th Feb 20169:49 amRNSBlocklisting Interim Review
28th Jan 20167:00 amRNSDirectorate Change
31st Dec 20157:00 amRNSTotal Voting Rights
15th Dec 20159:57 amRNSHolding(s) in Company
14th Dec 20158:26 amRNSHolding(s) in Company
14th Dec 20158:21 amRNSDirector/PDMR Shareholding
8th Dec 201511:46 amRNSHolding(s) in Company
8th Dec 201511:42 amRNSHolding(s) in Company
1st Dec 201510:52 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.